ARCUTIS BIOTHERAPEUTICS, INC. Comprehensive Income
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Comprehensive Income of $14.87 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- ARCUTIS BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $14.87M.
- ARCUTIS BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$11.77M.
- ARCUTIS BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $17.41M.
- ARCUTIS BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $7.38M.
- ARCUTIS BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$16.18M.
- ARCUTIS BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$140.05M.
- ARCUTIS BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$261.05M.
- ARCUTIS BIOTHERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$312.29M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $14.87M 10-Q · filed 2026-08-05 | $3.10M 10-Q · filed 2026-08-05 | $20.52M derived: sum of 3 quarters · filed 2026-08-05 | $27.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$11.77M 10-Q · filed 2026-05-06 | $5.65M derived: sum of 2 quarters · filed 2026-05-06 | $13.03M derived: sum of 3 quarters · filed 2026-05-06 | -$2.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $17.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $24.80M derived: sum of 2 quarters · filed 2026-02-25 | $9.02M derived: sum of 3 quarters · filed 2026-08-05 | -$16.18M 10-K · filed 2026-02-25 |
| 2025-09-30 | $7.38M 10-Q · filed 2025-10-28 | -$8.40M derived: sum of 2 quarters · filed 2026-08-05 | -$33.59M 10-Q · filed 2025-10-28 | -$44.92M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$15.78M 10-Q · filed 2026-08-05 | -$40.97M 10-Q · filed 2026-08-05 | -$52.30M derived: sum of 3 quarters · filed 2026-08-05 | -$93.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$25.19M 10-Q · filed 2026-05-06 | -$36.52M derived: sum of 2 quarters · filed 2026-05-06 | -$77.23M derived: sum of 3 quarters · filed 2026-05-06 | -$129.72M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$11.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$52.04M derived: sum of 2 quarters · filed 2026-02-25 | -$104.53M derived: sum of 3 quarters · filed 2026-02-25 | -$140.05M 10-K · filed 2026-02-25 |
| 2024-09-30 | -$40.71M 10-Q · filed 2025-10-28 | -$93.20M derived: sum of 2 quarters · filed 2025-10-28 | -$128.72M 10-Q · filed 2025-10-28 | -$194.82M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$52.49M 10-Q · filed 2025-08-06 | -$88.01M 10-Q · filed 2025-08-06 | -$154.11M derived: sum of 3 quarters · filed 2026-02-25 | -$198.76M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$35.52M 10-Q · filed 2025-05-06 | -$101.61M derived: sum of 2 quarters · filed 2026-02-25 | -$146.27M derived: sum of 3 quarters · filed 2026-02-25 | -$217.14M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | -$66.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$110.75M derived: sum of 2 quarters · filed 2026-02-25 | -$181.62M derived: sum of 3 quarters · filed 2026-02-25 | -$261.05M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$44.66M 10-Q · filed 2024-11-06 | -$115.53M derived: sum of 2 quarters · filed 2024-11-06 | -$194.95M 10-Q · filed 2024-11-06 | -$266.46M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$70.87M 10-Q · filed 2024-08-14 | -$150.30M 10-Q · filed 2024-08-14 | -$221.81M derived: sum of 3 quarters · filed 2025-02-25 | -$329.86M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$79.43M 10-Q · filed 2024-05-14 | -$150.94M derived: sum of 2 quarters · filed 2025-02-25 | -$258.99M derived: sum of 3 quarters · filed 2025-02-25 | -$326.63M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$71.51M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$179.56M derived: sum of 2 quarters · filed 2025-02-25 | -$247.20M derived: sum of 3 quarters · filed 2025-02-25 | -$312.29M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$108.05M 10-Q · filed 2023-11-03 | -$175.69M derived: sum of 2 quarters · filed 2023-11-03 | -$240.78M 10-Q · filed 2023-11-03 | -$312.34M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$67.64M 10-Q · filed 2023-08-08 | -$132.73M 10-Q · filed 2023-08-08 | -$204.29M derived: sum of 3 quarters · filed 2024-02-27 | -$261.25M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$65.09M 10-Q · filed 2023-05-09 | -$136.65M derived: sum of 2 quarters · filed 2024-02-27 | -$193.61M derived: sum of 3 quarters · filed 2024-02-27 | -$235.70M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$71.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$128.53M derived: sum of 2 quarters · filed 2024-02-27 | -$170.61M derived: sum of 3 quarters · filed 2024-02-27 | -$206.61M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$56.96M 10-Q · filed 2022-11-08 | -$99.05M derived: sum of 2 quarters · filed 2022-11-08 | -$135.05M 10-Q · filed 2022-11-08 | -$169.10M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$42.09M 10-Q · filed 2022-08-04 | -$78.08M 10-Q · filed 2022-08-04 | -$112.14M derived: sum of 3 quarters · filed 2023-02-28 | -$150.34M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$36.00M 10-Q · filed 2022-05-05 | -$70.05M derived: sum of 2 quarters · filed 2023-02-28 | -$108.25M derived: sum of 3 quarters · filed 2023-02-28 | -$143.68M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$34.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$72.25M derived: sum of 2 quarters · filed 2023-02-28 | -$107.69M derived: sum of 3 quarters · filed 2023-02-28 | -$135.68M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$38.20M 10-Q · filed 2021-11-04 | -$73.63M derived: sum of 2 quarters · filed 2021-11-04 | -$101.62M 10-Q · filed 2021-11-04 | -$114.19M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-06-30 | -$35.43M 10-Q · filed 2021-08-05 | -$63.42M 10-Q · filed 2021-08-05 | -$75.99M derived: sum of 3 quarters · filed 2022-02-22 | -$90.48M derived: sum of 4 quarters · filed 2022-02-22 |
| 2020-03-31 | -$27.99M 10-Q · filed 2021-05-06 | -$40.56M derived: sum of 2 quarters · filed 2022-02-22 | -$55.05M derived: sum of 3 quarters · filed 2022-02-22 | -$63.33M derived: sum of 4 quarters · filed 2022-02-22 |
| 2019-12-31 | -$12.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | -$27.05M derived: sum of 2 quarters · filed 2022-02-22 | -$35.34M derived: sum of 3 quarters · filed 2022-02-22 | -$42.00M 10-K · filed 2022-02-22 |
| 2019-09-30 | -$14.48M 10-Q · filed 2020-11-05 | -$22.77M derived: sum of 2 quarters · filed 2020-11-05 | -$29.43M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$8.29M 10-Q · filed 2020-08-11 | -$14.95M 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$6.66M 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | -$19.25M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |